US 10,376,463 B2
Ocular iontophoretic delivery of dexamethasone and formulations thereof
Mike Jaffe, East Hartford, CT (US); Gary Cook, Westford, MA (US); Perry Calias, Melrose, MA (US); and Michael A. Patane, Andover, MA (US)
Assigned to Eyegate Pharmaceuticals, Inc., Waltham, MA (US)
Filed by Mike Jaffe, East Hartford, CT (US); Gary Cook, Westford, MA (US); Perry Calias, Melrose, MA (US); and Michael A. Patane, Andover, MA (US)
Filed on May 11, 2012, as Appl. No. 13/469,481.
Application 13/469,481 is a division of application No. 12/391,836, filed on Feb. 24, 2009, abandoned.
Claims priority of provisional application 61/031,267, filed on Feb. 25, 2008.
Claims priority of provisional application 61/047,950, filed on Apr. 25, 2008.
Prior Publication US 2012/0283231 A1, Nov. 8, 2012
Int. Cl. A61K 9/00 (2006.01); A61N 1/04 (2006.01); A61F 9/00 (2006.01); A61K 31/573 (2006.01); A61K 41/00 (2006.01); A61N 1/30 (2006.01)
CPC A61K 9/0048 (2013.01) [A61F 9/0008 (2013.01); A61K 9/0009 (2013.01); A61K 31/573 (2013.01); A61K 41/00 (2013.01); A61N 1/0448 (2013.01); A61N 1/303 (2013.01); A61N 1/044 (2013.01)] 1 Claim
OG exemplary drawing
 
1. An aqueous dexamethasone phosphate formulation comprising: (1) dexamethasone phosphate at a concentration of 40 mg/mL; and (ii) a buffering agent, wherein said buffering agent adjusts the pH of said formulation to 5.7 to 5.8.